Physiological and QoL Benefits of Qi-Gong in Post-acute Sequelae of Covid-19

NCT ID: NCT06879925

Last Updated: 2025-03-17

Study Results

Results pending

The study team has not published outcome measurements, participant flow, or safety data for this trial yet. Check back later for updates.

Basic Information

Get a concise snapshot of the trial, including recruitment status, study phase, enrollment targets, and key timeline milestones.

Recruitment Status

RECRUITING

Clinical Phase

NA

Total Enrollment

80 participants

Study Classification

INTERVENTIONAL

Study Start Date

2024-12-02

Study Completion Date

2025-04-07

Brief Summary

Review the sponsor-provided synopsis that highlights what the study is about and why it is being conducted.

The goal of this clinical trial is to determine whether Qi-Gong can improve physiological function and quality of life (QoL) in individuals with post-acute sequelae of SARS-CoV-2 infection (PASC).

Study Objectives:

To assess whether Qi-Gong improves physiological function in individuals with PASC.

To evaluate whether Qi-Gong enhances quality of life in individuals with PASC.

Study Design:

If a comparison group is included, researchers will compare Qi-Gong with standard care to assess its effectiveness.

Participant Involvement:

Practice Qi-Gong three times per week for three months. Record physiological data monthly.

Detailed Description

Dive into the extended narrative that explains the scientific background, objectives, and procedures in greater depth.

Conditions

See the medical conditions and disease areas that this research is targeting or investigating.

PASC Post Acute Sequelae of COVID 19

Study Design

Understand how the trial is structured, including allocation methods, masking strategies, primary purpose, and other design elements.

Allocation Method

RANDOMIZED

Intervention Model

CROSSOVER

Experimental Group:QIGONG Control Group
Primary Study Purpose

SUPPORTIVE_CARE

Blinding Strategy

NONE

Study Groups

Review each arm or cohort in the study, along with the interventions and objectives associated with them.

Qi-Gong Group

Experimental Group :Qi-Gong(yijinjing)

Group Type EXPERIMENTAL

QI-GONG and control

Intervention Type BEHAVIORAL

QIGONG

routine care Group

Control Group:routine care

Group Type NO_INTERVENTION

No interventions assigned to this group

Interventions

Learn about the drugs, procedures, or behavioral strategies being tested and how they are applied within this trial.

QI-GONG and control

QIGONG

Intervention Type BEHAVIORAL

Eligibility Criteria

Check the participation requirements, including inclusion and exclusion rules, age limits, and whether healthy volunteers are accepted.

Inclusion Criteria

* PASC
* above 20 y/o

Exclusion Criteria

* Those who cannot cooperate
* Severe schizophrenia
Minimum Eligible Age

20 Years

Maximum Eligible Age

100 Years

Eligible Sex

ALL

Accepts Healthy Volunteers

No

Sponsors

Meet the organizations funding or collaborating on the study and learn about their roles.

POCHIWU

OTHER

Sponsor Role lead

Responsible Party

Identify the individual or organization who holds primary responsibility for the study information submitted to regulators.

POCHIWU

nurse态master's candidate

Responsibility Role SPONSOR_INVESTIGATOR

Principal Investigators

Learn about the lead researchers overseeing the trial and their institutional affiliations.

Mei-Hua Wang

Role: PRINCIPAL_INVESTIGATOR

National Taipei University of Nursing and Health Sciences

Locations

Explore where the study is taking place and check the recruitment status at each participating site.

Renhe nursing home

New Taipei City, , Taiwan

Site Status RECRUITING

Fuxi nursing home

Taipei, , Taiwan

Site Status RECRUITING

Countries

Review the countries where the study has at least one active or historical site.

Taiwan

Central Contacts

Reach out to these primary contacts for questions about participation or study logistics.

Po-Chi Wu

Role: CONTACT

+886900622739

Facility Contacts

Find local site contact details for specific facilities participating in the trial.

Manager

Role: primary

+886226365111

Manager

Role: primary

+886225919087

Other Identifiers

Review additional registry numbers or institutional identifiers associated with this trial.

NTUNHS

Identifier Type: REGISTRY

Identifier Source: secondary_id

CTH-113-3-5-030

Identifier Type: -

Identifier Source: org_study_id

More Related Trials

Additional clinical trials that may be relevant based on similarity analysis.